ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / LNSR
MBOT (29) QTEX (36) SKIN (32) LUCD (39) ⌘ Pro Terminal →

LENSAR Inc. (LNSR) — RQD Stock Rating Cockpit

$5.67 -2.91% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.63

LENSAR Inc. (LNSR) carries a Roarable Rating of E (Strong Sell) with 18/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $71.7M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LNSR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LNSR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, LENSAR Inc. (NASDAQ: LNSR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 18/100 at a spot price of $5.67 (-2.91% 1D, market cap $71.7M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, LNSR ranks #1003 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LNSR compare to MBOT and QTEX in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), LNSR carries a Roarable E (18/100 RQD), trailing P/E of N/A, gross margin of 39.4%, and ROIC of -35.0%. By comparison, MBOT (Microbot Medical Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -15.8%, cap $73.2M) and QTEX (QTREX Quantum Ltd.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $68.3M). Among the 5-stock peer group, LNSR leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LNSR?
▼

Per LNSR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001320350), LENSAR Inc. generated $51.7M in revenue (+12.4% YoY), -$34.3M in net income, and -$14.9M in free cash flow against $71.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $5.63 (-0.71%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (18/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510018
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E
Cash (3)Whales (3)SEC (5)Macro (5)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-18% Base Target
$14 Bull$5 Base$4 Bear
📬 FREE LNSR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LNSR)Realized 20D OHLCV Swing Band: ±7%
Deterministic 5-Pillar Attribution (18/100 Composite)
🔍 WHY LNSR SCORES 18/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+5/20 pts (28% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Macro Regime Fit+5/20 pts (28% of score)

FRED Regime × Technicals: 9% of 52W Range • RSI-14 at 34.6 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
26
Grade E$6.22-7.6% Next Q
Q2 (-2Q)
23
Grade E$5.75+3.7% Next Q
Q3 (-1Q)
21
Grade E$5.96-4.9% Next Q
Current
18
Grade E$5.67-12.2% Hist 90D α
Trajectory: E (26) → E (18)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LNSR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LNSR currently carries a cautious 18/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.04) and Max Pain ($5.95) forces dealer call-delta covering toward $13.59.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LNSR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LNSR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 18%NO 82%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
34.630 Oversold · 70 Hot
ALTMAN-Z SHIELDDISTRESS RISK (<1.8)
0.20>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
4 / 99-Pt Accounting
52-WEEK LASER RANGE9% OF RANGE
L: $5$5.67H: $13
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 2 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 6 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 10 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on LNSR

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (15)

-35.0% ROIC with 39.4% gross margin and -20.33% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (25)

Altman-Z 0.20 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (18)

6/40 institutional & smart-money positioning score with 5/20 macro alignment.

Bull Case: Why Buyers Like LNSR
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LNSR)

  • ✓Walkthrough of LNSR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
LNSR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +1.98%📐 HORIZONTAL RANGE
2026-11-03O $5.97H $5.97L $5.67C $5.67VOL 28.8K
RES: $11.02SUP: $4.69SMA50: $7.04SMA200: $7.42
$11.31$9.58$7.86$6.14$4.42RES $11.02SUP $4.69$5.672026-05-042026-06-172026-08-042026-09-172026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LNSR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LNSR Butterfly Map → + Track LNSR →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +12.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on LNSR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LNSR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LNSR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LNSR)

Health Care Rank #1003 of 1015 ⚔️ MBOT vs LNSR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LNSR vs. MBOT, QTEX, SKIN, LUCD)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, LENSAR Inc. (LNSR) ranks #1003 by composite RQD confidence (18/100, grade E) and #694 by equity capitalization ($71.7M). Within this direct 5-issuer industry benchmark cohort, LNSR leads on earnings valuation at N/A trailing P/E, while MBOT leads on capital efficiency and profitability with -15.8% ROIC and — gross margin. LUCD currently holds the highest overall quantitative score in the immediate peer group at 39/100 (D-) compared with LNSR at 18/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
LNSR ACTIVE
LENSAR Inc.
E 18/100 — 39.4% -35.0% -2.91% $71.7M Benchmark Subject
MBOT
Microbot Medical Inc.
E 29/100 — — -15.8% -4.59% $73.2M /mbot-vs-lnsr →
QTEX
QTREX Quantum Ltd.
D- 36/100 — 0.7% -35.0% -8.20% $68.3M /qtex-vs-lnsr →
SKIN
SkinHealth Systems Inc. (Class A)
E 32/100 — 65.3% -26.9% +4.43% $64.7M /skin-vs-lnsr →
LUCD
Lucid Diagnostics Inc.
D- 39/100 — — -35.0% +0.37% $82.3M /lucd-vs-lnsr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001320350 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), LENSAR Inc. (LNSR) reported GAAP revenue of $51.7M (+12.4% vs. FY2024 revenue of $46.0M , and +44.6% cumulative change since FY2023) , GAAP net income of -$34.3M, operating cash flow of -$14.8M, and free cash flow of -$14.9M (-513.5% YoY). On the balance sheet, LNSR closed FY2025 with $71.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $51.7M -$34.3M -$14.8M -$14.9M $71.4M —
FY2024 (FY) 2024-12-31 $46.0M -$31.4M -$2.3M -$2.4M $66.3M —
FY2023 (FY) 2023-12-31 $35.7M -$14.4M -$9.7M -$9.7M — —

3. LNSR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LNSR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, LENSAR Inc. (NASDAQ: LNSR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 18/100 at a spot price of $5.67 (-2.91% 1D, market cap $71.7M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, LNSR ranks #1003 in composite RQD confidence.

How does LNSR compare to MBOT and QTEX in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), LNSR carries a Roarable E (18/100 RQD), trailing P/E of N/A, gross margin of 39.4%, and ROIC of -35.0%. By comparison, MBOT (Microbot Medical Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -15.8%, cap $73.2M) and QTEX (QTREX Quantum Ltd.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $68.3M). Among the 5-stock peer group, LNSR leads on earnings multiple (N/A) while MBOT leads on capital efficiency (-15.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LNSR?

Per LNSR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001320350), LENSAR Inc. generated $51.7M in revenue (+12.4% YoY), -$34.3M in net income, and -$14.9M in free cash flow against $71.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LNSR trading relative to its 50-day, 200-day, and 52-week technical levels?

LNSR last traded at $5.67 (-2.91% on volume of 70,194 shares), positioning the stock -19.46% below its 50-day simple moving average ($7.04) and -23.58% below its 200-day simple moving average ($7.42). Across its 52-week range of $4.95 to $12.94, LNSR sits at the 9.0% percentile with a 14-day RSI of 34.6 (NEUTRAL RANGE) and an implied next-earnings move of ±7.0% ($5.27 to $6.07).

Direct Sub-Reports: LNSR RQD Cockpit LNSR 12M Forecast LNSR Earnings & Move LNSR Dividends & DRIP LNSR Insiders & 13F LNSR Whale Options LNSR Profit Sankey LNSR News & Why
ROARABLE RATING BRIEF • RQD 18/100 (E) ✓ SEC XBRL & RQD VERIFIED

LNSR — LENSAR Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

LENSAR Inc. (LNSR) earns a live Roarable RQD composite score of 18/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $5.67 (-2.91% 1D, market capitalization $71.7M).

  • Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 39.4%, operating margin of -47.6%, and free cash flow yield of -20.33%.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (5/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. Is a NASDAQ-listed issuer in the Health Care sector and Medical/Dental Instruments industry. — describes its specific products, customers, or revenue model. The profile reports a market capitalization of $0.1B. Reported gross margin is 39.4%, indicating the company retains a portion of revenue after direct costs.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), LENSAR Inc. (LNSR) reported $51.7M in annual revenue (up from $46.0M in FY2024, +12.4% YoY) and -$34.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($35.7M revenue, -$14.4M net income) through FY2025, LNSR scaled operating cash flow to -$14.8M and free cash flow to -$14.9M, backed by $71.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 18/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -20.33% and institutional whale pillar of 3/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $4.95 – $12.94 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -47.6% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream dependencies are mapped (supply_chain: NONE, butterfly_links: empty).

  • Key Question #1: Can LNSR sustain or expand its -47.6% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $51.7M and free cash flow of -$14.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is LNSR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

LNSR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for LENSAR Inc. (LNSR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LNSR Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LNSR Bull vs. Bear Conversation Board — What's Your Call at $5.67?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LNSR 🐻 33% BEARISH CONVICTION
1. Pick Your Side on LNSR:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $6.83 (+17.0%)
📌 Pinned Debate

Institutional accumulation and options positioning score 8/20, the strongest pillar, with revenue growing from $35.7M in FY 2023 to $51

The street is overcomplicating LENSAR Inc. (LNSR). Institutional accumulation and options positioning score 8/20, the strongest pillar, with revenue growing from $35.7M in FY 2023 to $51.7M in FY 2025.. With an RQD score of 18/100 (E) and Forensic Balance Sheet at 5/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $6.31.

VolSurface_Trader 🐂 BULL

Both sides have a point here — LNSR's 5/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $4.79 (-18.0%)
Spot @ $5.84

ROIC of -35%, FCF yield of -20.33%, and an Altman Z-Score of 0.2 indicate weak cash generation and elevated forensic balance-sheet risk

Sitting on the sidelines or leaning short LNSR above $5.84. ROIC of -35%, FCF yield of -20.33%, and an Altman Z-Score of 0.2 indicate weak cash generation and elevated forensic balance-sheet risk.. Until Fundamental Cash Engine (2/20) and FCF yield (-20.33%) inflect higher, upside is capped near $12.94.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%